SELLAS Life Sciences Group, Inc. (SLS) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | Payments of Dividends |
| Net income · 12 months | -32.46M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-32.46M | (m) |
| 2026-03-31 | (m) | $-29.46M | (m) |
| 2025-12-31 | (m) | $-26.86M | (m) |
| 2025-09-30 | (m) | $-25.94M | (m) |
| 2025-06-30 | (m) | $-26.26M | (m) |
| 2025-03-31 | (m) | $-27.13M | (m) |
| 2024-12-31 | (m) | $-30.88M | (m) |
| 2024-09-30 | (m) | $-32.28M | (m) |
| 2024-06-30 | (m) | $-34.44M | (m) |
| 2024-03-31 | (m) | $-35.81M | (m) |
| 2023-12-31 | (m) | $-37.34M | (m) |
| 2023-09-30 | (m) | $-38.33M | (m) |
| 2023-06-30 | (m) | $-36.08M | (m) |
| 2023-03-31 | (m) | $-35.65M | (m) |
| 2022-12-31 | (m) | $-41.30M | (m) |
| 2022-09-30 | (m) | $-38.78M | (m) |
| 2022-06-30 | (m) | $-38.84M | (m) |
| 2022-03-31 | (m) | $-35.04M | (m) |
| 2021-12-31 | (m) | $-20.70M | (m) |
| 2021-09-30 | (m) | $-17.82M | (m) |
| 2021-06-30 | (m) | $-15.21M | (m) |
| 2021-03-31 | (m) | $-15.02M | (m) |
| 2020-12-31 | (m) | $-16.76M | (m) |
| 2020-09-30 | (m) | $-20.46M | (m) |
| 2020-06-30 | (m) | $-20.19M | (m) |
| 2020-03-31 | (m) | $-18.90M | (m) |
| 2019-12-31 | $0.00 | $-19.29M | 0.00% |
| 2019-09-30 | $0.00 | $-25.20M | 0.00% |
| 2019-06-30 | $376.00K | $-21.28M | -1.77% |
| 2019-03-31 | (m) | $-24.21M | (m) |
| 2018-12-31 | $487.00K | $-27.67M | -1.76% |
| 2018-09-30 | (m) | $-23.13M | (m) |
| 2018-06-30 | (m) | $-27.30M | (m) |
| 2018-03-31 | (m) | $-27.15M | (m) |
| 2017-12-31 | (m) | $-23.75M | (m) |
| 2017-09-30 | (m) | $-31.71M | (m) |
| 2017-06-30 | (m) | $-32.57M | (m) |
| 2017-03-31 | (m) | $-18.77M | (m) |
| 2016-12-31 | (m) | $-23.55M | (m) |
| 2016-09-30 | (m) | $-37.71M | (m) |
| 2016-06-30 | (m) | $-48.81M | (m) |
| 2016-03-31 | (m) | $-69.86M | (m) |
| 2015-12-31 | (m) | $-63.90M | (m) |
| 2015-09-30 | (m) | $-52.18M | (m) |
| 2015-06-30 | (m) | $-40.33M | (m) |
| 2015-03-31 | (m) | $-44.61M | (m) |
| 2014-12-31 | (m) | $-36.61M | (m) |
| 2014-09-30 | (m) | $-77.15M | (m) |
| 2014-06-30 | (m) | $-80.27M | (m) |
| 2014-03-31 | (m) | $-69.92M | (m) |
| 2013-12-31 | (m) | $-76.68M | (m) |
| 2013-09-30 | (m) | $-31.93M | (m) |
| 2013-06-30 | (m) | $-28.90M | (m) |
| 2013-03-31 | (m) | $-19.50M | (m) |
| 2012-12-31 | (m) | $-34.97M | (m) |
| 2012-09-30 | (m) | $-29.63M | (m) |
| 2012-06-30 | (m) | $-28.84M | (m) |
| 2012-03-31 | (m) | $-32.41M | (m) |
| 2011-12-31 | (m) | $-11.48M | (m) |
| 2011-09-30 | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) |
| 2010-12-31 | (m) | $-11.99M | (m) |
| 2010-09-30 | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |